Should Ipilimumab Be the New “Standard” for Refractory MCC?

2024
Merkel Cell Carcinoma
Ipilimumab
Ipi/Nivo
We discuss the role of Ipilimumab in anti-PD1 refractory MCC
Author

David M. Miller

Published

May 3, 2024

Event

3rd International Symposium on Merkel Cell Carcinoma, MD Anderson Cancer Center

Slides

You can view the slides for the presentation here

This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement